Shostka G D
Folia Haematol Int Mag Klin Morphol Blutforsch. 1981;108(6):769-77.
Iron stores, ferrokinetics and total bone marrow cellularity were determined in 35 hemodialysis patients. Some of the patients received hemotransfusions (group I), the others (group II) androgens and iron supplements. In group I the blood losses amounted to 23.9 +/- 2.4 ml/d, in group II to 7.7 +/- 0.5 ml/d. Serum iron and ferritin levels exceeded the normal values. Iron stores were 0.31 +/- 0.07 mg/100 mg (group I) and 0.25 +/- 0.05 mg/100 mg /100 mg (group II), whereas the normal values are 0.18 +/- 0.02 mg/100 mg desferrioxamine. Total bone marrow cellularity in patients of group I amounted to 8.3 +/- 2.3 . 10(9) cells/kg, and in group II to 27.4 +/- 3.2 . 10(9) cells/kg, while the normal values are 14.1 +/- 1.4 . 10(9) cells/kg. Hemotransfusions suppress considerably ferrokinetic indexes in dialysis patients. In massive blood losses hemotransfusions are the therapy of choice for the anemia, but they suppress blood formation. to correct iatrogenic blood losses, iron and androgens may be administered thus stimulating blood formation.
对35例血液透析患者测定了铁储备、铁动力学和全骨髓细胞计数。部分患者接受了输血（第一组），其他患者（第二组）接受了雄激素和铁补充剂。第一组的失血量为23.9±2.4 ml/天，第二组为7.7±0.5 ml/天。血清铁和铁蛋白水平超过正常值。铁储备在第一组为0.31±0.07 mg/100 mg，在第二组为0.25±0.05 mg/100 mg，而去铁胺的正常值为0.18±0.02 mg/100 mg。第一组患者的全骨髓细胞计数为8.3±2.3×10⁹细胞/千克，第二组为27.4±3.2×10⁹细胞/千克，而正常值为14.1±1.4×10⁹细胞/千克。输血会显著抑制透析患者的铁动力学指标。在大量失血时，输血是治疗贫血的首选方法，但会抑制血液生成。为纠正医源性失血，可给予铁和雄激素以刺激血液生成。
